VideoThe merger-and-acquistion focus was on Canada last week, with natural resources suitors in Toronto and Calgary accounting for four of the top 10 North American deals.
Two other deals involved targets outside the continent — led by the week's biggest deal: Bank of America Corp.'s $7.07-billion purchase of 8 percent of China construction Bank Corp. from the state-owned China SAFE Investments. When the dealmaking was done, only four transactions reflected U.S. companies buying other U.S. companies. And the largest of those was Eli Lilly's $150-million purchase of United Therapeutics, according to data provided to CFO.com by mergermarket.
Meanwhile, a ripple in mid-sized deals announced just today seems to foreshadow more activity for when this week's tally is reported. The largest was diversified health care-products company Johnson & Johnson saying it would pay $438 million for Omrix Biopharmaceuticals Inc. In the defense sector, L-3 Communications agreed to acquire Chesapeake Sciences Corp., a maker of anti-submarine warfare systems. Also, engineering and construction company Fluor Corp. acquired two private European engineering companies, and toymaker Jakks Pacific Inc. agreed to buy Halloween costume and decoration company Disguise Inc., with the last two deals having undisclosed terms.
Also today, Alpharma Inc. finally agreed to King Pharmaceuticals Inc.'s $1.6 billion cash takeover offer, ending the months-long battle by Bristol, Tenn.-based King for Bridgewater, N.J.-based Alpharma.
For the week ended Sunday, dealmakers struck 31 agreements worth $2.54 billion, in terms of North American companies purchased. In the prior week, 36 transactions totaled $54.54 billion. Year to date, 3,420 deals have been valued at $991.02 billion, still far short of last year's record 4,605 deals, worth $1.45 trillion, as of this time.
Bank of America Corp. to buy 8-percent stake in China Construction Bank Corp. from China SAFE Investments Ltd. for $7.07 billion
Charlotte-based Bank of America is exercising a call option to acquire 8.35 of Bejing-based China Construction Bank from China SAFE Investments, China's state-owned investment company. Terms call for BofA to purchase 19,580,153,370 H shares of China Construction Bank at a price 1.2 times CCB's audited net assets valuation per share on Sept. 30. The per-share price represents a discount of 32.4 percent. After the transaction, expected to close by Nov. 30, BofA will hold approximately 19.13 percent of CCB's issued share capital.
Seller financial advisor: Not Disclosed
Bidder financial advisor: Bank of America
Seller legal advisor: Not Disclosed
Bidder legal advisor: Cleary Gottlieb Steen & Hamilton; Deacons
ProEx Energy Ltd. to buy Progress Energy Trust for $1.16 billion
Calgary, Canada-based Progress Energy, an open-ended, unincorporated energy investment trust, definitively agreed to be acquired by ProEx, a Calgary-based petroleum and natural-gas exploration, development, and production company. Both boards have approved the merger at $8.75 a share, a premium of 13 percent. The implied equity value is about $919.2 million for the transaction, expected to close in the first quarter of 2009.
Seller financial advisor: BMO Capital Markets
Bidder financial advisor: Peters & Co
Seller legal advisor: Blake Cassels & Graydon; Burnet Duckworth & Palmer
Bidder legal advisor: Macleod Dixon
HudBay Minerals Inc. to buy Lundin Mining Corp. for $843 million
Vancouver, Canada-based Lundin, a diversified base metals mining company with operations in Portugal, Spain, Sweden, and Ireland, produces copper, nickel, lead, and zinc. It agreed to be acquired by Toronto-based HudBay for 0.3919-share of HudBay for each Lundin share in a transaction expected to close by next May 30.
Seller financial advisor: Haywood Securities
Bidder financial advisor: GMP Securities
Seller legal advisor: McCullough O'Connor; Osler Hoskin & Harcourt; Shearman & Sterling
Bidder legal advisor: Cassels Brock & Blackwell; Fraser Milner Casgrain; White & Case
Eli Lilly to buy United Therapeutics for $150 million
Silver Spring, Md.-based biotechnology company United Therapeutics, which focuses on the development and commercialization of products for cardiovascular and infectious diseases and cancer, signed a license and a supply agreement to be acquired by Indianapolis-based Lilly, which discovers, develops, manufactures, and sells pharmaceutical and animal-health products.
Seller financial advisor: Leerink Swann
Bidder financial advisor: Internal
Seller legal advisor: Gibson Dunn & Crutcher
Bidder legal advisor: Latham & Watkins
Reader Comments» Post a comment